Details for Patent: 6,414,126
✉ Email this page to a colleague
Summary for Patent: 6,414,126
| Title: | C-aryl glucoside SGLT2 inhibitors and method |
| Abstract: | SGLT2 inhibiting compounds are provided having the formulawhereR1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R5b, -CO2H, -COR6b, -CH(OH)R6c, -CH(OR5h)R6d, -CONR6R6a, -NHCOR5c, -NHSO2R5d, -NHSO2Aryl, Aryl, -SR5e, -SOR5f, -SO2R5g, -SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl;R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle;A is O, S, NH, or (CH2)n where n is 0-3.A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent. |
| Inventor(s): | Bruce Ellsworth, William N. Washburn, Philip M. Sher, Gang Wu, Wei Meng |
| Assignee: | AstraZeneca AB |
| Application Number: | US09/679,027 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,414,126 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 6,414,126
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,414,126
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1506211 | ⤷ Start Trial | C300585 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | PA2013008 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | 122013000033 | Germany | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | C20130006 00074 | Estonia | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | 92182 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | 2013/013 | Ireland | ⤷ Start Trial |
| European Patent Office | 1506211 | ⤷ Start Trial | CA 2013 00019 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
